Literature DB >> 30078796

[FGFR1-mutated B-cell acute lymphoblastic leukemia transforming to myelodysplastic / myeloproliferative neoplasm and acute myeloid leukemia].

Shiro Ide1, Shin Ohara1, Morihiro Inoue1, Jian Hua1, Masao Hagihara1.   

Abstract

A 77-year-old male with hyperleukocytosis and thrombocytopenia was diagnosed with Philadelphia chromosome (Ph) -negative B-cell acute lymphoblastic leukemia (ALL) ; he was treated with induction chemotherapy. Despite an initial complete remission, hyperleukocytosis was returned 18 months later. A bone marrow smear revealed a substantial increase in the number of myeloid cells with each stage of differentiation, which was markedly different from the initial presentation, resulting in the diagnosis of Ph-negative myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). After a month, an autopsy revealed that the disease had progressed to acute myelogenous leukemia (AML). Since the first diagnosis, a chromosomal translocation, t (8;13) (p12;q12), was identified; this was subsequently confirmed by fluorescence in situ hybridization (FISH) analysis to comprise a genomic rearrangement of the fibroblast growth factor receptor 1 (FGFR1) gene. Collectively, this is a rare case of a myeloid/lymphoid neoplasm with an FGFR1 genomic rearrangement that initially presented as B-cell ALL, before developing into MDS/MPN and finally into AML. In the literature, although a transformation of MPN into ALL is often reported, the transformation of B-cell ALL into MPN is an infrequent event.

Entities:  

Keywords:  Acute lymphoblastic leukemia (ALL); FGFR1; MDS/MPN; t(8;13)(p12;q12)

Mesh:

Substances:

Year:  2018        PMID: 30078796     DOI: 10.11406/rinketsu.59.872

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

Review 1.  Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review.

Authors:  Meifang Zhao; Jingnan Sun; Shanshan Liu; Hongqiong Fan; Yu Fu; Yehui Tan; Sujun Gao
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.